A high-resolution genomic and phenotypic analysis of resistance evolution of an Escherichia coli strain from a critically unwell patient treated with piperacillin/tazobactam
Journal of Medical Microbiology · 2025
DOI: 10.1099/jmm.0.002018 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Medical Microbiology, 2025. Verfasst von Alice J Fraser und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK. Hauptthemen laut MEDLINE: Escherichia coli, Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents, Escherichia coli Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Foundation, Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Introduction
Resistance to the β -lactam/ β -lactamase inhibitor (BL/BLI) combination antibiotic piperacillin/tazobactam (TZP) predominantly occurs via β -lactamase enzymes, also leading to resistance to third-generation cephalosporins (3GCs). However, if β -lactamases inactive against 3GCs and inhibited by tazobactam are expressed at high levels, leading to enzyme hyperproduction, the surplus enzyme escapes inhibition by tazobactam and inactivates the antibiotic piperacillin. Hypothesis/Gap statement. Understanding this mechanism is clinically relevant, as enzyme hyperproduction can emerge upon antibiotic administration, resulting in treatment failure despite initial resistance profiles supporting TZP use.
Aim
Our aim was to determine whether this was a case of within-patient evolution and by what mechanism or an acquisition of a second unrelated, more resistant, strain. Methodology. Whole-genome sequencing was performed on the isolate to determine the genetic basis of resistance. We also assessed the impact of TZP exposure on the amplification of the bla TEM-1 gene and monitored the stability of gene copy number over 5 days in the absence of antibiotic pressure. In addition, we determined the MICs of ceftriaxone and TZP, with TZP MIC contextualized in relation to gene copy number and resistance levels.
Results
We report the identification of an Escherichia coli isolate that developed resistance to TZP during patient treatment but maintained sensitivity to ceftriaxone. We show that TZP resistance evolved via IS 26 -mediated duplication of a bla TEM-1 containing transposable unit on a plasmid, resulting in hyperproduction of TEM-1 β -lactamase, and that ten copies of bla TEM-1 induce resistance greater than 32 times the MIC. Furthermore, under experimental conditions, exposure to TZP further increases amplification of bla TEM-1 , whereas, in the absence of TZP, gene copy number of IS 26 and bla TEM-1 remains stable over 5 days, despite a 48,205 bp genome size increase compared to the pre-amplification isolate. We additionally detect phenotypic changes that might indicate host adaptation potentially linked to the additional genes that are amplified.
Conclusion
Our analysis advances the understanding of infections caused by isolates evolving β -lactamase hyperproduction, which represents a complex problem in both detection and treatment. As 40% of antibiotics active against WHO priority pathogens in the pre-clinical pipeline are BL/BLI combinations, further investigations are of urgent concern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK.
- Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L7 8XP, UK.
- Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK.
- School of Science, Engineering and Environment, University of Salford, Manchester, M5 4WT, UK.
- Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK.
- Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK.
Förderung
- Wellcome Trust
- Medical Research Foundation
- Biotechnology and Biological Sciences Research Council
- Royal Academy of Engineering
Zitieren
APA
Fraser, A. J., Ball, R., Cantillon, D., Brettell, L. E., Graf, F. E., Munnoch, J. T., Hoskisson, P. A., Lewis, J. M., van Aartsen, J. J., Parry, C. M., Heinz, E., & Edwards, T. (2025). A high-resolution genomic and phenotypic analysis of resistance evolution of an Escherichia coli strain from a critically unwell patient treated with piperacillin/tazobactam. Journal of Medical Microbiology. https://doi.org/10.1099/jmm.0.002018
Vancouver
Fraser AJ, Ball R, Cantillon D, Brettell LE, Graf FE, Munnoch JT, et al. A high-resolution genomic and phenotypic analysis of resistance evolution of an Escherichia coli strain from a critically unwell patient treated with piperacillin/tazobactam. Journal of Medical Microbiology. 2025. doi:10.1099/jmm.0.002018
BibTeX
@article{Fraser2025,
author = {Fraser, Alice J and Ball, Robert and Cantillon, Daire and Brettell, Laura E and Graf, Fabrice E and Munnoch, John T and Hoskisson, Paul A and Lewis, Joseph M and van Aartsen, Jon J and Parry, Christopher M and Heinz, Eva and Edwards, Thomas},
title = {A high-resolution genomic and phenotypic analysis of resistance evolution of an Escherichia coli strain from a critically unwell patient treated with piperacillin/tazobactam},
journal = {Journal of Medical Microbiology},
year = {2025},
doi = {10.1099/jmm.0.002018}
}
EUVIMED